Personalized therapy for cardiovascular disease

12 enero 2015

Researchers have announced results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39 percent in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths. These patients also benefit from a reduction in the amount of atherosclerosis in their vessels. This discovery may also pave the way for a new era in cardiovascular medicine, with personalized or precision drugs.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/l3RjwFTOOd4/150112181327.htm

Volver